SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Omada Health (OMDA) has a negative trailing P/E of -54.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 26.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -1.84%, forward earnings yield 3.85%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+99%).
- Forward P/E 26.0 — analysts expect a return to profitability with estimated EPS of $0.48 for FY2028.
- Trailing Earnings Yield -1.84% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 3.85% as earnings recover.
- Analyst consensus target $24.80 (+99% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 63/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — OMDA
Valuation Multiples
P/E (TTM)-54.4
Forward P/E26.0
PEG RatioN/A
Forward PEGN/A
P/B Ratio3.03
P/S Ratio2.69
EV/EBITDA-73.9
Per Share Data
EPS (TTM)$-0.22
Forward EPS (Est.)$0.48
Book Value / Share$3.93
Revenue / Share$4.45
FCF / Share$0.27
Yields & Fair Value
Earnings Yield-1.84%
Forward Earnings Yield3.85%
Dividend Yield0.00%
SharesGrow IV$9.58 (-23.1%)
Analyst Target$24.80 (+99%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2022 |
-17.7 |
0.00 |
8.24 |
14.38 |
- |
| 2023 |
-19.0 |
2.74 |
12.96 |
10.44 |
- |
| 2024 |
-27.2 |
0.91 |
19.84 |
7.55 |
- |
| 2025 |
-72.2 |
0.97 |
4.01 |
3.54 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2022 |
$0.00 |
$89.19M |
$-72.52M |
-81.3% |
| 2023 |
$0.00 |
$122.78M |
$-67.51M |
-55% |
| 2024 |
$0.00 |
$169.8M |
$-47.14M |
-27.8% |
| 2025 |
$-0.22 |
$260.21M |
$-12.78M |
-4.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.10 |
$-0.10 – $-0.10 |
$318.89M |
$316.49M – $321.28M |
4 |
| 2027 |
$-0.02 |
$-0.03 – $-0.02 |
$383.15M |
$377.18M – $389.1M |
3 |
| 2028 |
$0.52 |
$0.51 – $0.53 |
$453.27M |
$453.25M – $453.29M |
1 |
